source
- Early Inclusion of China Boosts Global Biotech Clinical Development EfficiencyMany global biotech firms still treat China as a later-stage commercial market, adding it only after key development decisions. This practice often forces costly bridging studies, extends timelines…
- Akeso reports phase 3 overall survival win for ivonescimab in advanced biliary tract cancerAkeso announced that its bispecific antibody ivonescimab combined with chemotherapy improved overall survival in a China phase 3 trial for advanced biliary tract cancer, beating the standard regime…